Abstract library

5 results for "Goodman".
#1263 Pretherapy Identification of Patients at Risk of Receiving a High Renal Dose Undergoing Peptide Receptor Radionuclide Therapy
Introduction: 68GaDOTA TATE imaging of patients with neuroendocrine tumours has shown that tumour sequestration is a major factor leading to a sink effect that decreases activity concentration in healthy tissues, particularly the renal parenchyma.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Steven Goodman
Keywords: dosimetry, PRRT
#1425 Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate.
Introduction: Lutetium-177 DOTA-octreotate (LuTate), a radiolabelled somatostatin analogue, delivers targeted radiation to neuroendocrine tumours and metastases. Healthy tissues also receive significant irradiation. Charged amino acids are routinely co-infused to block renal proximal tubular LuTate reabsorption. Gelofusine® (a succinylated bovine gelatin molecule), proposed to interact with the megalin/cubulin receptor-mediated transporter system, has been shown to reduce renal uptake of indium-111 octreotide. Routine Gelofusine® administration is limited by risk of allergic reaction.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Catherine Lucas
Authors: Lucas C, Goodman S, Smith J, Burge M, ...
#2066 Pretherapeutic Predictors of Tumor Absorbed Dosimetry in Radionuclide Therapy for Metastatic Neuroendocrine Tumors
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate Positron Emission Tomography (68Ga-DOTATATE PET) standardised uptake value (SUV) has shown conflicting results in the prediction of tumour lesion absorbed dosimetry (TLAD).
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Pattison D, Smith J, Goodman S, ...
#2069 Tumor Absorbed Dosimetry and Response of Radionuclide Therapy in Metastatic Neuroendocrine Tumor
Introduction: Increased tumour lesion absorbed dosimetry (TLAD) from peptide receptor radionuclide therapy (PRRT) is associated with neuroendocrine tumours (NET) response. Responses to PRRT might be impacted by NET grade, site of origin and use of concurrent chemotherapy.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Pattison D, Smith J, Goodman S, ...
#2119 Positron Emission Tomography (PET) Predictors of Tumor Response to Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors (NET)
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate (68Ga-DOTATATE) PET standardised uptake value (SUV) has shown conflicting results in the prediction of tumour response to radionuclide therapy.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Pattison D, Smith J, Goodman S, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.